The parasitic helminth Schistosoma mansoni (S. mansoni) is a major public health concern in many developing countries. 
INTRODUCTION
Despite the mass chemotherapy programs, schistosome reinfection rates and prevalence continue to be unexpectedly high. Similarly rebound prevalence and morbidity will be high; an evitable consequence if ongoing interventions are not sustained 1 . Furthermore, there is increasing concern about the development of parasite resistance to chemotherapy. Consequently, vaccine strategies represent an essential component for the future control of schistosomiasis as an adjunct to chemotherapy 2 . Schistosomes are truly a formidable adversary that won't easily be beaten. It has been shown that hosts can develop an acquired immunity against challenge infection either after primary infection, immunization with irradiated larvae, or with defined antigens 3, 4 . A vaccine would enhance attempts to control and eradicate the disease that currently relies on treatment with a single drug
5
. An effective schistosome vaccine is a desirable control tool but progress towards that goal has been slow 6 . Attempts to develop a schistosome vaccine began half a century ago. By analogy with successful microbial and viral vaccines, they involved the vaccination of mice with crude worm extracts or purified components, followed by a cercarial challenge 7 . Perhaps there were a few key antigens that needed to be identified 6 . So, a particular attention was thus given to identify and characterize sensitive and specific S. mansoni antigens to obtain better diagnostic tool and vaccine development 8 . A few defined soluble antigens were separated to show high sensitivity and specificity in endemic areas 9 . Vaccines in combination with other control strategies, including the use of new drugs, are needed to make elimination of schistosomiasis possible
10
. Despite the discovery and publication of numerous potentially promising vaccine antigens from S. mansoni and, to a lesser extent, Schistosoma hematobium, only one vaccine, namely, BILHVAX, or the 28-kDa GST from Schistosoma hematobium, has entered clinical trials
11
. By reviewing the most recent and pertinent data on the major vaccine antigens for schistosomiasis; the available antigens and prototype vaccine formulations induce 40 to 50% protection in animals, at best as shown by reduced worm burden or egg production and viability 2 .
The aim of the present research was the isolation of a cDNA clones from 7-days schistosomula λgt11cDNA library which could be a targets for immune attack and hopefully vaccine candidates for S. mansoni elimination. Antibodies bound to the column were eluted by 0.1 M glycine-HCl, pH 2.6 and collected as 1 ml fractions. The pH of the elute was immediately adjusted to 7.0 with 100 µl 1M Trisbase., then, it was dialyzed against PBS over night to be ready for immunoscreening.
MATERIALS & METHODS
Immunoscreening of schistosomula λgt11 cDNA library 14 . To grow cells for transfection with the library, a single colony of E.Coli Y1090 was incubated in 50 ml LBampicillin medium (LB-amp) (10 g Bacto-tryptone,5 g Bacto-yeast extract, 10 g NaCl and distilled H 2 O up to 1L , pH 7.0 ) containing 0.2% maltose and ampicillin 100 mg/ml allowed to grow overnight at 37 o C, to be used as hosts for plating the library. For the primary screening of the library, 150 mm LB-amp plates were used and 90 mm plates were used for secondary and tertiary screenings. 0.6 ml / large plate and 0.2 ml / small one of the overnight bacterial culture was incubated with 0.1 ml of SM medium (5.8 g NaCl, 2.0 g MgSO 4 .7 H 2 O, 50 ml 1M Tris , pH 7.5 and 5 ml of 2% gelatin solution/L). The cell suspension was incubated at 37 o C for 15 min to allow the adsorption of the phage to the bacterial cells. 7 ml / large plate and 3.5 ml / small plate of the molten top agar was cooled to 50 o C and added to the infected cells, then, poured onto the LB-amp plates pre-warmed to 37 o C. The plates were incubated at 40 o C for 3-4 hours (hrs). Dry nitrocellulose (132 mm and 82 mm) circular filters were used for large and small plates, respectively. The filters were saturated in 10 mM IPTG and air dried, then, placed onto the plates. The plates were transferred to a 37 o C incubator for another 3 hrs. then, the filters were removed from the plates and transferred to the Blotto buffer [5g non fat dry milk /100 ml TBST (37.5 ml 4M NaCl , 10 ml 1M Tris; pH 8.0, double distilled H 2 O up to 1L and 0.05% Tween-20 )] to block the non-specific binding protein sites. The filters were ,then, washed 3 times in TBST for 10 min each, followed by incubation for 3 hrs with the purified sera over schistosomula soluble extract column (primary antibody)
, then, washed 4 times at room temperature (RT) in TBST for 20 min each. The anti-rabbit IgG alkaline phosphatase conjugate (secondary antibody) diluted in TBST was incubated with the primary antibody-antigen complex for 1 hr at RT. Then, the filters were washed 4 times in TBST for 10 min each, dried and transferred to the colour development substrate solution [33 µl of 50 mg/ml Nitro Blue Tetrazolium (NBT) + 16.5 µl of 50 mg/ml BCIP/ml AP buffer (10 ml of M Tris; pH 9.5, 2 ml of 5 M NaCl 0.5 ml of 1 M MgCl, distilled H 2 O up to 100 ml)]. The filters were incubated in dark until the desired colour intensity had been developed, then, rinsed in distilled H 2 O. The developed filters were used to pick up agar plugs containing phage particles corresponding to the signals on the filters (the positive plaques) to be suspended into 0.5 ml of SM medium. The purified phage plaques were used for the next round of screening.
Polymerase Chain Reaction (PCR)
15
. The isolated phage DNA was amplified using a pair of primers, λgt11 forward Small scale preparation of plasmid DNA 18 . A single bacterial colony that contains the desired plasmid was used to inoculate 100 ml of LB-amp medium incubated at 37 o C with vigorous overnight shaking (O/N). The bacterial cells were centrifuged at 10000 rpm for 10 min. For cells lysis solution I was used (50 mM glucose, 25 mM Tris HCl, pH 8, 10 mM EDTA, pH 8) and freshly prepared lysozyme was added, then, followed by solution II [0.2 M NaOH, 1% sodium dodecyl sulphate (SDS)], the suspension was incubated at room temperature (RT) for 10 min followed by adding 20 ml of solution III (3 M potassium acetate, 2 M glacial acetic acid). DNA was recovered by adding an equal volume of isopropanol and precipitated by centrifugation at 10000 rpm for 10 min at RT. The pelleted DNA was dissolved in 100 µl distilled H 2 O to which RNase (10 mg/ml) was added, M urea gel), the run was continued for 2.5 and 6.5 hrs.. After the electrophoresis, the gel was fixed in a solution of 10% acetic acid and 10% methanol for 30 min, dried by heating, then, exposed to an X-ray film, which was developed and the information obtained from DNA sequence was analyzed using the Genetics Computer Group Sequence analysis Software package.
RESULTS
Sera obtained from S. mansoni chronically infected patients were purified over an antigen coupled column made from soluble extract of 7-days schistosomula. The elute containing affinity purified antibodies was used to immunoscreen 7-days schistosomula λgt11 cDNA library. One of the identified cDNA clones by affinity purified antibodies (clone 4-65) contained a 0.9 kb insert. The full DNA sequence of the clone showed a single open reading frame (ORF) of 269 amino acids with high identity (94%) to the gene of SJCHGC 03921 protein of Schistosoma japonicum.
The 0.9 clone which was completely sequenced in both directions after being inserted into PCR TM II vector, did not contain the entire coding region. The 5 / -upstream region in the sequence obtained showing that the first initiation codon (ATG) is located -201 bp from the beginning of this region with neither transcription activation TATA nor CAAT boxes. There are three putative polyadenylation signals AAATAA, AATTA and ATAA located +114, +22 and +6 bp, respectively, from the 3 / -downstream region, there is no polyadenylation site (poly A tail) (Fig.  1) .Some of the isolated clones were checked for their sizes after being inserted in the plasmid vector using two restriction enzymes EcoR1 and BamH1 (Fig. 2) , all clones showed no BamH1 site, while, being digested by EcoR1 gave the actual size of each insert. The selected clone was sequenced using two primers (M13 from the 5 /-end and T7 from the 3 / -end) followed by another two pairs of primers to complete the sequence of the isolated clone, each sequence gel was exposed to an X-ray film for 24 hrs, then, developed and read from the bottom of the autoradiogram (Fig. 3) . The development of vaccine against schistosomiasis would provide a powerful tool for the control of this important parasitic disease and it must be effective which should be confirmed by protection test
21
. Several vaccine strategies have been tried such as the use of synthetic peptides 22 . The tegument associated antigens expressed on newly transformed and developing schistosomules and involved in important host-parasite interactions are important candidates for vaccine development 23 . The current research was focusing on identification, characterization and study of the vaccine potential of tegumental and internal antigens of 7-days schistosomula. The technique used was not the extraction of surface proteins only, but all the parasite was sonicated for obtaining all antigens either they are tegumental or internal. After three rounds of immunoscreening of λgt11 cDNA library of 7-days schistosomula by affinity purified antibodies obtained from the sera of patients, a number of cDNA clones were isolated, one of them (clone 4-65) was amplified by PCR using λgt11 forward and reverse primers , then , cloned in PCR TM II vector. The size of the selected clone was shown to be 0.9 kb by checking the pattern of restriction endonuclease digestion using EcoR1 and BamH1 enzymes, the result of enzymatic digestion was run on 1% agarose gel, the digestion by EcoR1 proved the size of the insert. The DNA sequence did not contain the entire coding region of the gene. The upstream region the transcription activation boxes (TATA and CAAT) were not found, similarly, there is no polyadenylation site in the downstream region. The DNA sequence of the identified clone showed that it has (94%) homology with the gene that encodes SJCHGC 03921 protein of Schistosoma hematobium. 24 reported some of the most promising S. mansoni vaccine antigens as well as those that were independently tested under the umbrella of the TDR/WHO committee in the mid-1990s, the group of isolated antigens includes tetraspanins, although their functions are unknown, but a family of them is expressed in the schistosome tegument and at least three of these show promise as vaccines.
Sm23 is a tetraspanin expressed in the tegument of S. mansoni and is one of the independently tested WHO/TDR vaccine candidates, it is the most efficacious when delivered as a DNA vaccine 25 and does not confer protection as a recombinant protein when formulated with alum.
Sm28-GST has GST properties and is expressed in subtegumental tissues of most developmental stages of the parasite. Vaccination of semipermissive rats and permissive hamsters with recombinant Sm28-GST resulted in significant reductions of worms 26 There is an abundance of reports on schistosome antigens obtained from different anatomic locations and stages of the developing parasite. The tegument antigens of a live worm are those that researchers focus efforts are truly exposed to the host immune system, so, the tegument plasma membrane proteins should be a major focus for future vaccinology efforts 33 , because a focus on identification of new intracellular antigens show moderate protection at best 34 . The deficits in lipid metabolism that makes schistosomes dependent on the host are revealed and the identification of membrane receptors, ion channels and more than 300 proteases provide new insights into the biology of the life cycle and novel targets 35 . There is shortage of informations about the isolated gene in this study which advocate continuing the efforts to perform further researches for picking up the full length gene, identifying its localization, its function and its vaccine potential. 
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